Want to see AU:CYP full AI Analyst Report?
Total Valuation
Cynata Therapeutics Limited has a market cap or net worth of AU$2.68M. The enterprise value is AU$77.99.
Market CapAU$2.68M
Enterprise ValueAU$77.99
Share Statistics
Cynata Therapeutics Limited has 243,454,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding243,454,380
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cynata Therapeutics Limited’s return on equity (ROE) is 23.06 and return on invested capital (ROIC) is 2416.48%.
Return on Equity (ROE)23.06
Return on Assets (ROA)-6.71
Return on Invested Capital (ROIC)2416.48%
Return on Capital Employed (ROCE)24.16
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover1.26
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cynata Therapeutics Limited is ―. Cynata Therapeutics Limited’s PEG ratio is 0.02.
PE Ratio―
PS Ratio1.94
PB Ratio-8.41
Price to Fair Value-8.41
Price to FCF-0.49
Price to Operating Cash Flow-0.39
PEG Ratio0.02
Income Statement
In the last 12 months, Cynata Therapeutics Limited had revenue of 1.71M and earned -9.09M in profits. Earnings per share was -0.04.
Revenue1.71M
Gross Profit1.71M
Operating Income-9.53M
Pretax Income-9.09M
Net Income-9.09M
EBITDA-7.55M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -6.74M and capital expenditures 0.00, giving a free cash flow of -6.74M billion.
Operating Cash Flow-6.74M
Free Cash Flow-6.74M
Free Cash Flow per Share-0.03
Dividends & Yields
Cynata Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change-94.76%
50-Day Moving Average0.01
200-Day Moving Average0.21
Relative Strength Index (RSI)28.06
Average Volume (3m)410.90K
Important Dates
Cynata Therapeutics Limited upcoming earnings date is Feb 25, 2027, TBA (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateFeb 25, 2027
Ex-Dividend Date―
Financial Position
Cynata Therapeutics Limited as a current ratio of 0.64, with Debt / Equity ratio of 0.00%
Current Ratio0.64
Quick Ratio0.64
Debt to Market Cap0.00
Net Debt to EBITDA0.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cynata Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cynata Therapeutics Limited EV to EBITDA ratio is -0.32, with an EV/FCF ratio of -0.36.
EV to Sales1.41
EV to EBITDA-0.32
EV to Free Cash Flow-0.36
EV to Operating Cash Flow-0.36
Balance Sheet
Cynata Therapeutics Limited has AU$897.42K in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$897.42K billion.
Cash & Marketable SecuritiesAU$897.42K
Total DebtAU$0.00
Net CashAU$897.42K
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share>-AU$0.01
Margins
Gross margin is 0.00%, with operating margin of -556.59%, and net profit margin of -531.03%.
Gross Margin0.00%
Operating Margin-556.59%
Pretax Margin-531.03%
Net Profit Margin-531.03%
EBITDA Margin-441.39%
EBIT Margin-456.59%
Analyst Forecast
The average price target for Cynata Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast15.04%